LRRC72: A Potential Drug Target and Biomarker (G100506049)

Target Name: LRRC72

NCBI ID: G100506049

LRRC72

LRRC72: A Potential Drug Target and Biomarker

The long non-coding RNA (lncRNA) landscape has experienced a surge in the recent years, with the identification of numerous functional lncRNAs that play critical roles in various cellular processes. One of these lncRNAs is LRRC72, which has been identified in various cellular contexts and is known to participate in various cellular processes, including cell adhesion, migration, and invasion. The unique feature of LRRC72 is its potential to serve as a drug target and biomarker, making it an attractive target for researchers to investigate.

Drug Target Potential

The drug targeting potential of LRRC72 is derived from its various functions in cellular processes. LRRC72 has been shown to be involved in cell-cell adhesion, which is a critical process for the maintenance of tissue architecture and cell-surface interactions. LRRC72 has been shown to regulate the formation of tight junctions, which are a type of cell-cell adhesion, and is essential for maintaining the integrity of tissues. Additionally, LRRC72 has been shown to be involved in the regulation of cell migration and invasion, which are critical processes for the development and maintenance of tissues and organs.

The potential drug targets for LRRC72 are numerous and diverse. One of the main targets is the PI3K/Akt signaling pathway, which is a well-established target for many diseases, including cancer. The PI3K/Akt signaling pathway is involved in the regulation of various cellular processes, including cell growth, differentiation, and survival. LRRC72 has been shown to be involved in the regulation of PI3K/Akt signaling pathway, which suggests that it may be a potential drug target for cancer therapies.

Another potential drug target for LRRC72 is the TGF-β signaling pathway, which is involved in the regulation of cell growth, differentiation, and survival. LRRC72 has been shown to be involved in the regulation of TGF-β signaling pathway, which suggests that it may be a potential drug target for diseases that are characterized by TGF-β-related pathologies, such as cancer and neurodegenerative diseases.

Biomarker Potential

The potential use of LRRC72 as a biomarker is based on its unique expression patterns in various cellular contexts. LRRC72 has been shown to be highly expressed in various tissues and has been associated with various diseases, including cancer. By using qRT-PCR, RNA levels of LRRC72 have been shown to be significantly increased in various cancer types, including breast, ovarian, and colorectal cancers. Additionally, LRRC72 has been shown to be involved in the regulation of cell cycle progression, which is a critical process for the development and maintenance of cancer cells.

In conclusion, LRRC72 is a promising drug target and biomarker due to its diverse functions in cellular processes. The potential targets for LRRC72 are numerous and diverse, including the PI3K/Akt and TGF-β signaling pathways, and its potential use as a biomarker for various diseases. Further research is needed to fully understand the role of LRRC72 in cellular processes and its potential as a drug target and biomarker.

Protein Name: Leucine Rich Repeat Containing 72

The "LRRC72 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LRRC72 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets